Merck

Merck to cut another 8,500 jobs, sharpen pipeline, shutter facilities

Wednesday, October 2, 2013 12:37 PM

In a move to create greater efficiencies, Merck announced the elimination of another 8,500 positions, in addition to previously reported reductions of 7,500 jobs, with a goal of paring annual operating expenses by approximately $2.5 billion by the end of 2015.

More... »

Merck to continue development of Tecemotide in phase III trial

Tuesday, October 1, 2013 10:30 AM

Merck Serono, the biopharmaceutical division of Merck, has decided to continue clinical development of the investigational MUC1 antigen-specific cancer immunotherapy tecemotide  (also known as L-BLP25 and formerly known as Stimuvax). Merck Serono, which is developing tecemotide under a license agreement with Oncothyreon, will conduct a new phase III trial called START2 for patients with unresectable, locally advanced stage III non-small cell lung cancer (NSCLC).

More... »

Global Health Investment Fund launched for late-stage vaccines

Friday, September 27, 2013 10:59 AM

A new investment fund structured by JPMorgan Chase and the Bill & Melinda Gates Foundation will, for the first time, allow individual and institutional investors the opportunity to finance late-stage global health technologies that have the potential to save millions of lives in low-income countries.

More... »

AstraZeneca, Merck enter license agreement for cancer

Wednesday, September 11, 2013 01:43 PM

AstraZeneca and Merck have announced a worldwide licensing agreement for Merck’s oral small molecule inhibitor of WEE1 kinase, MK-1775, currently being evaluated in phase IIa clinical studies in combination with standard of care therapies for the treatment of patients with certain types of ovarian cancer.

More... »

ObsEva, Merck Serono ink license agreement

Friday, August 30, 2013 02:23 PM

ObsEva, a Swiss-based, specialty biopharmaceutical company, signed a licensing agreement with Merck Serono, the biopharmaceutical division of Germany-based Merck, granting ObsEva worldwide development and commercialization rights to certain Merck Serono compounds for preterm labor. The details of the agreement were not disclosed. The funding will allow ObsEva to undertake the development of these compounds.

More... »

Ashfield names Michael Burman VP Medical Call Center

Monday, August 19, 2013 08:48 AM

Ashfield, part of United Drug, has named Dr. Michael Burman vice president of its Ivyland, Pa-based Medical Call Center. Ashfield Medical Information, formerly Alliance Healthcare, is a provider of medical information and pharmacovigilance call center services to healthcare, biotech and device companies.

More... »

Avanir, Merck announce diabetes co-promotion agreement

Thursday, August 15, 2013 12:30 PM

Avanir Pharmaceuticals has entered into an exclusive, multi-year agreement with Merck to co-promote Merck's type 2 diabetes therapies Januvia (sitagliptin) and the sitagliptin family of products in the long-term care institutional setting in the U.S.

More... »

Bionomics, Merck ink $172 million research collaboration

Thursday, August 1, 2013 11:31 AM

Bionomics has announced an agreement with Merck to discover and develop novel small molecule candidates for the treatment of chronic pain, including neuropathic pain. The initial period of the research program will be two years. 

More... »

Gentris names Amelia Wall president

Friday, July 26, 2013 03:12 PM

Gentris, a pharmacogenomics and biorepository solutions company, has named Dr. Amelia Wall Warner its new president. Warner will oversee U.S. operations, lead the development of new service offerings and develop scientific education and training programs for biobanking and pharmacogenomics.

More... »

Biogen Idec, Adimab expand collaboration

Friday, July 26, 2013 03:05 PM

Adimab, a provider of an integrated antibody discovery and optimization platform, has expanded its collaboration with Biogen Idec for the discovery of antibody-based therapeutics. 

More... »